| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast … M Marty, F Cognetti, D Maraninchi, R Snyder, L Mauriac, M Tubiana-Hulin, ... Journal of clinical oncology 23 (19), 4265-4274, 2005 | 2018 | 2005 |
| Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non–small-cell lung cancer F Cardenal, MP López-Cabrerizo, A Antón, V Alberola, B Massuti, ... Journal of Clinical Oncology 17 (1), 12-12, 1999 | 595 | 1999 |
| Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head … R Hitt, A López-Pousa, J Martínez-Trufero, V Escrig, J Carles, A Rizo, ... J Clin Oncol 23 (34), 8636-8645, 2005 | 584 | 2005 |
| Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ... The Lancet Oncology 17 (10), 1386-1395, 2016 | 439 | 2016 |
| PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers RRL Bastien, Á Rodríguez-Lescure, MTW Ebbert, A Prat, B Munárriz, ... BMC medical genomics 5, 1-12, 2012 | 399 | 2012 |
| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 332 | 2020 |
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer M Martín, Á Rodríguez-Lescure, A Ruiz, E Alba, L Calvo, M Ruiz-Borrego, ... Journal of the National Cancer Institute 100 (11), 805-814, 2008 | 297 | 2008 |
| First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase … E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ... The oncologist 17 (1), 15-25, 2012 | 273 | 2012 |
| Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and … M Martin, A Lluch, MA Segui, A Ruiz, M Ramos, E Adrover, ... Annals of oncology 17 (8), 1205-1212, 2006 | 262 | 2006 |
| Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm … F Montemurro, S Delaloge, CH Barrios, R Wuerstlein, A Anton, E Brain, ... Annals of Oncology 31 (10), 1350-1358, 2020 | 253 | 2020 |
| Adjuvant docetaxel for high-risk, node-negative breast cancer M Martín, MA Seguí, A Antón, A Ruiz, M Ramos, E Adrover, I Aranda, ... New England Journal of Medicine 363 (23), 2200-2210, 2010 | 253 | 2010 |
| Liposomal doxorubicin in the treatment of breast cancer patients: a review J Lao, J Madani, T Puértolas, M Álvarez, A Hernández, R Pazo-Cid, ... Journal of drug delivery 2013, 2013 | 213 | 2013 |
| Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish … LG Paz-Ares, E Solsona, E Esteban, A Saez, J Gonzalez-Larriba, A Anton, ... Journal of Clinical Oncology 28 (18_suppl), LBA4518-LBA4518, 2010 | 197 | 2010 |
| A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer J Tabernero, MA Climent, A Lluch, J Albanell, JB Vermorken, A Barnadas, ... Annals of oncology 15 (9), 1358-1365, 2004 | 181 | 2004 |
| A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study E Alba, JI Chacon, A Lluch, A Anton, L Estevez, B Cirauqui, E Carrasco, ... Breast cancer research and treatment 136, 487-493, 2012 | 179 | 2012 |
| Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP … L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ... Annals of Oncology 33 (5), 534-543, 2022 | 165 | 2022 |
| Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study M Martín, S Loibl, G von Minckwitz, S Morales, N Martinez, A Guerrero, ... Journal of Clinical Oncology 33 (9), 1045-1052, 2015 | 164 | 2015 |
| Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer S Chan, G Romieu, J Huober, T Delozier, M Tubiana-Hulin, ... Journal of Clinical Oncology 27 (11), 1753-1760, 2009 | 153 | 2009 |
| Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with … L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ... JAMA oncology 4 (3), 302-308, 2018 | 145 | 2018 |
| Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study LG Estévez, JM Cuevas, A Antón, J Florián, JM López-Vega, A Velasco, ... Clinical cancer research 9 (2), 686-692, 2003 | 127 | 2003 |
